# Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)

> **NCT05943223** · PHASE2 · UNKNOWN · sponsor: **McMaster Children's Hospital** · enrollment: 16 (estimated)

## Conditions studied

- Appendicitis Perforated

## Interventions

- **DRUG:** Piperacillin/tazobactam
- **DRUG:** Normal saline
- **DRUG:** CefTRIAXone Injection
- **DRUG:** Metronidazole Injection

## Key facts

- **NCT ID:** NCT05943223
- **Lead sponsor:** McMaster Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2024-09
- **Final completion:** 2024-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943223, "Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05943223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*